Skip to main content

Showing 1–3 of 3 results for author: Roberts, K

Searching in archive stat. Search in all archives.
.
  1. arXiv:2509.07267  [pdf, ps, other

    stat.ME stat.AP

    Monitoring Adverse Events Through Bayesian Nonparametric Clustering Across Studies

    Authors: Shijie Yuan, Kevin Roberts, Noirrit Kiran Chandra, Yuan Ji, Peter Müller

    Abstract: We introduce a Bayesian nonparametric inference approach for aggregate adverse event (AE) monitoring across studies. The proposed model seamlessly integrates external data from historical trials to define a relevant background rate and accommodates varying levels of covariate granularity (ranging from patient-level details to study-level aggregated summary data). Inference is based on a covariate-… ▽ More

    Submitted 8 September, 2025; originally announced September 2025.

  2. arXiv:2406.19597  [pdf, ps, other

    stat.ME

    What's the Weight? Estimating Controlled Outcome Differences in Complex Surveys for Health Disparities Research

    Authors: Stephen Salerno, Emily K. Roberts, Belinda L. Needham, Tyler H. McCormick, Fan Li, Bhramar Mukherjee, Xu Shi

    Abstract: In this work, we are motivated by the problem of estimating racial disparities in health outcomes, specifically the average controlled difference (ACD) in telomere length between Black and White individuals, using data from the National Health and Nutrition Examination Survey (NHANES). To do so, we build a propensity for race to properly adjust for other social determinants while characterizing th… ▽ More

    Submitted 16 September, 2025; v1 submitted 27 June, 2024; originally announced June 2024.

  3. arXiv:2211.15826  [pdf, other

    stat.ME

    Surrogacy Validation for Time-to-Event Outcomes with Illness-Death Frailty Models

    Authors: Emily K. Roberts, Michael R. Elliott, Jeremy M. G. Taylor

    Abstract: A common practice in clinical trials is to evaluate a treatment effect on an intermediate endpoint when the true outcome of interest would be difficult or costly to measure. We consider how to validate intermediate endpoints in a causally-valid way when the trial outcomes are time-to-event. Using counterfactual outcomes, those that would be observed if the counterfactual treatment had been given,… ▽ More

    Submitted 28 November, 2022; originally announced November 2022.